# Selinexor & Talazoparib in Advanced Refractory Solid Tumors; Advanced/Metastatic Triple Negative Breast Cancer (START)

Source: https://onco.cc/trials/nct05035745/  
OnCo record `nct05035745` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of talazoparib and selinexor in triple-negative breast cancer, run by National University Hospital, Singapore, now recruiting.

## Summary

Selinexor & Talazoparib in Advanced Refractory Solid Tumors; Advanced/Metastatic Triple Negative Breast Cancer (START) is a phase 1/2, interventional study registered as NCT05035745 by National University Hospital, Singapore, with a registry enrolment figure of 63 participants, started 2021-03-01 and due to reach its primary completion in 2027-11. Interventions recorded: Talazoparib; Selinexor. Conditions listed: Advanced Refractory Solid Tumors; Advanced Triple Negative Breast Cancers; Metastatic Triple Negative Breast Cancers. Triple-negative eligibility wording from the registry: "b) Dose expansion phase: Patients with previously treated, advanced or metastatic histologically or cytologically confirmed triple negative breast cancers". Sites: Singapore. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-24
- Tags: ctgov-ingest; tnbc-deep-dive
- Registry id: NCT05035745
- Phase: 1/2
- Setting: Phase I Dose Finding Study of Selinexor and Talazoparib in Patients With Advanced Refractory Solid Tumors, Followed by Phase II Expansion Cohort Study in Patients With Advanced/ Metastatic Triple Negative Breast Cancers. (START)
- Sponsor: National University Hospital, Singapore
- Enrolled: 63

## Sources

- ClinicalTrials.gov NCT05035745: https://clinicaltrials.gov/study/NCT05035745

## Connected records

- cancers: [Metastatic triple-negative breast cancer](https://onco.cc/cancers/tnbc-metastatic/)
- technologies: [PARP inhibitors](https://onco.cc/technologies/parp-inhibitor/)
- drugs: [Selinexor](https://onco.cc/drugs/selinexor/), [Talazoparib](https://onco.cc/drugs/talazoparib/)
- terms: [Triple-negative breast cancer trials open today (registry snapshot and UK sites)](https://onco.cc/terms/tnbc-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct05035745.json